Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Important advances in the understanding of the biology and mechanisms of tumor
progression of urothelial carcinoma (UC) have been achieved over the past decade. The …

Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and
cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional …

Purpose To compare long-term survival in patients with locally advanced or metastatic
transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or …

Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …

Gemcitabine, a pyrimidine nucleoside antimetabolite, is one of the most promising new
cytotoxic agents. The drug has shown activity in a variety of solid tumors, and has been …

Background Cisplatin-based chemotherapy is a standard treatment of metastatic urothelial
carcinoma (UC), though carboplatin-based chemotherapy is frequently substituted due to …

BACKGROUND A prospective, randomized Phase III trial was performed to determine
whether, compared with gemcitabine (GEM) alone, the addition of cisplatin (CDDP) to GEM …

OBJECTIVES: This phase 2 randomized study compared the toxicity and assessed the
efficacy of gemcitabine–cisplatin (GP) and gemcitabine–carboplatin (GC) in patients with …